{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:22:21Z","timestamp":1790626941756,"version":"4.1.0"},"reference-count":47,"publisher":"Impact Journals, LLC","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2021,11,23]]},"DOI":"10.18632\/oncotarget.28134","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T17:44:58Z","timestamp":1637343898000},"page":"2375-2387","source":"Crossref","is-referenced-by-count":25,"title":["Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052\/484 spheroids"],"prefix":"10.18632","volume":"12","author":[{"given":"Dylan AJ","family":"Gendre","sequence":"first","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, 1211 Geneva 4, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edis","family":"Ameti","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, 1211 Geneva 4, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Karenovics","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, 1211 Geneva 4, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Perriraz-Mayer","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, 1211 Geneva 4, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Triponez","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, 1211 Geneva 4, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Serre-Beinier","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, 1211 Geneva 4, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Manegold","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"38","author":"Gervais","year":"2016","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"39","author":"Cornelissen","year":"2021","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"2","author":"Urban","year":"2019","journal-title":"Lancet Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Baas","year":"2019","journal-title":"Lancet Respir Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","volume":"1","author":"Burgers","year":"2018","journal-title":"J Thorac Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"7","author":"Bray","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"8","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"35","author":"Johnson","year":"2006","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"37","author":"Felip","year":"2015","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"37","author":"Arrieta","year":"2015","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"37","author":"Wilner","year":"2014","journal-title":"N Engl J Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"36","author":"Yang","year":"2009","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"S1556","DOI":"10.21037\/jtd.2018.03.54","article-title":"A review of guidelines for lung cancer","volume":"1","author":"Di Maio","year":"2018","journal-title":"J Thorac Dis"},{"key":"14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ejcts\/ezaa158","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"5","author":"Durieux","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity","volume":"17","author":"Duarte","year":"2018","journal-title":"Cell"},{"key":"16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","volume":"17","author":"Anderson","year":"2018","journal-title":"Cell"},{"key":"17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"16","author":"Yu","year":"2015","journal-title":"Cell"},{"key":"18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"15","author":"Ramazanoglu","year":"2014","journal-title":"Cell"},{"key":"19","doi-asserted-by":"publisher","first-page":"e100300","DOI":"10.15252\/embj.2018100300","article-title":"Long-term expanding human airway organoids for disease modeling","volume":"3","author":"Proost","year":"2019","journal-title":"EMBO J"},{"key":"20","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","article-title":"Patient-derived lung cancer organoids ascancer models for therapeutic screening","volume":"1","author":"Taylor","year":"2019","journal-title":"Nat Commun"},{"key":"21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fonc.2020.00388","article-title":"The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models","volume":"1","author":"Jean","year":"2020","journal-title":"Front Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1038\/s41598-018-21200-8","article-title":"patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening","volume":"8","author":"Skardal","year":"2018","journal-title":"Sci Rep"},{"key":"23","doi-asserted-by":"publisher","first-page":"1247125","DOI":"10.1126\/science.1247125","article-title":"Organogenesis in a dish: modeling development and disease using organoid technologies","volume":"34","author":"Knoblich","year":"2014","journal-title":"Science"},{"key":"24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrm2236","article-title":"The third dimension bridges the gap between cell culture and live tissue","volume":"8","author":"Stelzer","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","article-title":"Spheroid-based drug screen: considerations and practical approach","volume":"4","author":"Kunz-Schughart","year":"2009","journal-title":"Nat Protoc"},{"key":"26","doi-asserted-by":"publisher","first-page":"e0238862","DOI":"10.1371\/journal.pone.0238862","article-title":"Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids","volume":"1","author":"Parsons","year":"2020","journal-title":"PLoS One"},{"key":"27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/2472555219830087","article-title":"3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis","volume":"2","author":"Danen","year":"2019","journal-title":"SLAS Discov"},{"key":"28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2014.12.004","article-title":"Spherical cancer models in tumor biology","volume":"1","author":"Dangles-Marie","year":"2015","journal-title":"Neoplasia"},{"key":"29","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/pharmaceutics12121186","article-title":"Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research","volume":"1","author":"Bousbaa","year":"2020","journal-title":"Pharmaceutics"},{"key":"30","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/cancers11101446","article-title":"In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes","volume":"1","author":"Zarogiannis","year":"2019","journal-title":"Cancers (Basel)"},{"key":"31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jinorgbio.2014.07.018","article-title":"Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?","volume":"14","author":"Osella","year":"2014","journal-title":"J Inorg Biochem"},{"key":"32","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1039\/c3lc51093j","article-title":"A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids","volume":"1","author":"Guenat","year":"2014","journal-title":"Lab Chip"},{"key":"33","doi-asserted-by":"publisher","first-page":"9176357","DOI":"10.1155\/2016\/9176357","article-title":"Spheroid Culture of Mesenchymal Stem Cells","volume":"201","author":"Tamama","year":"2016","journal-title":"Stem Cells Int"},{"key":"34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00441-005-0148-2","article-title":"Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and beta1-integrin","volume":"32","author":"Chang","year":"2006","journal-title":"Cell Tissue Res"},{"key":"35","doi-asserted-by":"publisher","first-page":"e0150044","DOI":"10.1371\/journal.pone.0150044","article-title":"Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma","volume":"1","author":"Broaddus","year":"2016","journal-title":"PLoS One"},{"key":"36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1471-2407-14-304","article-title":"Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity","volume":"1","author":"Karoubi","year":"2014","journal-title":"BMC Cancer"},{"key":"37","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3892\/or.2015.4200","article-title":"Inhibition of Src family kinases overcomes anoikis resistance induced by spheroid formation and facilitates cisplatin-induced apoptosis in human mesothelioma cells","volume":"3","author":"Fujimori","year":"2015","journal-title":"Oncol Rep"},{"key":"38","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3390\/ijms22041633","article-title":"Multicellular 3D Models to Study Tumour-Stroma Interactions","volume":"2","author":"Cattaneo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-019-0553-9","article-title":"Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA\/B and NKG2A targeting for cancer treatment","volume":"7","author":"Le Bourhis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13046-019-1257-1","article-title":"Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures","volume":"3","author":"Troiani","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids","volume":"17","author":"Depla","year":"2018","journal-title":"Cell"},{"key":"42","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1083\/jcb.201702033","article-title":"Cancer-associated fibroblasts lead tumor invasion through integrin-\u03b23-dependent fibronectin assembly","volume":"21","author":"Vignjevic","year":"2017","journal-title":"J Cell Biol"},{"key":"43","doi-asserted-by":"publisher","first-page":"E11671","DOI":"10.1073\/pnas.1803718115","article-title":"Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture","volume":"11","author":"Geles","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-019-1050-1","article-title":"GSK-3\u03b2 regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models","volume":"3","author":"Seo","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12885-016-2634-1","article-title":"Recapitulating epithelial tumor microenvironmentusing three dimensional tri-culture of human epithelial, endothelial, and mesenchymal cells","volume":"1","author":"Shastri","year":"2016","journal-title":"BMC Cancer"},{"key":"46","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"31","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"47","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/ijms19071881","article-title":"Experimental Model of Human Malignant Mesothelioma in Athymic Mice","volume":"1","author":"Serre-Beinier","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T16:46:55Z","timestamp":1637686015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":47,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,7,9]]}},"alternative-id":["28134"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28134","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]}}}